Cross-Sector entity
Adage Capital Partners GP L.L.C. is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. market-trends accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. We currently track 2 Cross-Sector stories that mention Ensysce Biosciences, Inc., all published on August 13, 2026.
2 verified stories tracked
Last mentioned: Aug 13, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Adage Capital Partners GP L.L.C. is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. market-trends accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. We currently track 2 Cross-Sector stories that mention Ensysce Biosciences, Inc., all published on August 13, 2026. Each carries 2 original sources on average.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Ensysce Biosciences, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Ensysce Biosciences short interest soared 619.9% to 364,278 shares as its stock trades at $0.30, while Focus Universal posted just $0.05M in quarterly revenue. The data highlights severe financial fragility across two small healthcare and device innovators.
SCYNEXIS shorts collapsed 87.6% to 320,181 shares, signaling bear exhaustion, while Ensysce Biosciences short interest exploded 619.9% to 364,278. Focus Universal also saw a 282.8% build, reflecting a stark divergence in microcap biotech sentiment.
Source: tickerreport.com · dailypolitical.com
